Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Glow Blend (sometimes written "GLOW") is a commercial pre-mixed combination of three peptides — BPC-157, GHK-Cu, and TB-500 — supplied in a single lyophilized vial by research-peptide vendors and some compounding pharmacies. The exact ratio of the three components varies by supplier, but a common preparation contains roughly equal milligram amounts of each peptide co-lyophilized in a 40 mg or 70 mg vial.
The blend is marketed within research-peptide channels for "skin and aesthetic" protocols. It is important to be precise about what the product is: a commercial convenience product that combines pre-existing peptides in a single vial. The combination has not been evaluated as a single product in any clinical study, and its components have not been tested together in any published trial.
History
The "Glow" name originated in research-peptide retail marketing in the late 2010s. There is no scientific publication describing the blend, no pharmacokinetic study of the mixed product, and no published rationale for the specific ratios used. The three component peptides have separate research histories:
- BPC-157 was characterized in the early 1990s by the Sikiric lab in Zagreb. Almost all efficacy evidence comes from rodent wound and tendon models.
- GHK-Cu was isolated by Loren Pickart in 1973 and is best documented as a topical cosmetic ingredient.
- TB-500 is the 17–23 fragment of Thymosin Beta-4, used originally in equine veterinary medicine.
Regulatory status
No regulator has reviewed or approved Glow Blend as a product. The individual components also lack approval: BPC-157 was placed in Category 2 of the FDA's 503A bulk substances list in 2023, GHK-Cu is approved only as a topical cosmetic ingredient, and TB-500 is on the WADA prohibited list. The blend is sold through research-chemical suppliers labeled for laboratory use only.
How researchers describe its action
Because the combination has not been studied as a unit, descriptions of its action are extrapolated from the individual component literature:
- BPC-157 is described in preclinical work as a modulator of nitric oxide signaling and VEGFR2 expression, with reported effects on tendon, gut, and vascular healing.
- GHK-Cu is documented in cell and topical animal studies as a stimulator of collagen and elastin synthesis, an antioxidant, and a copper carrier for lysyl oxidase.
- TB-500 carries the actin-binding motif of Thymosin Beta-4 and is described as a promoter of cell migration into wound beds.
Whether the three peptides interact pharmacologically when co-administered, whether the combined dose changes the kinetics of any component, and whether the combination produces effects distinct from the components alone — none of these questions has been addressed in published research.
Half-life and dosing intervals
The half-lives of the three components differ:
- BPC-157: approximately 15–30 minutes.
- GHK-Cu: approximately 30–60 minutes.
- TB-500: approximately 1.5–3 hours.
Observational protocols circulated in research-peptide channels typically describe subcutaneous injection of the blend once daily or every other day, with the total mass per injection commonly described in the 1–3 mg range across the three peptides combined. None of these regimens is derived from a controlled clinical study.
Reconstitution example
Glow Blend is typically supplied as a 40 mg or 70 mg lyophilized vial containing all three peptides. A 70 mg vial reconstituted with 2 mL of bacteriostatic water yields a total peptide concentration of 35 mg/mL. On a 1 mL U-100 insulin syringe, 5 units (0.05 mL) contains approximately 1.75 mg of total peptide mass, distributed across the three components in the ratio set by the supplier.
When working with a blend, the per-component mass is only as reliable as the supplier's labeling. Independent third-party content assays for these products are uncommon. Vial's calculator can be set to the total vial mass and water volume; per-component dose then depends on the supplier-reported ratio.
What to know
- No combined clinical data. The blend has not been studied as a single product in any peer-reviewed publication.
- Component regulatory status. BPC-157 is restricted by the FDA from US compounding; GHK-Cu is approved only as a topical cosmetic; TB-500 is WADA-banned. Injecting any of these for therapeutic purposes is outside approved use.
- Storage. Lyophilized blends should be refrigerated and protected from light. Once reconstituted, refrigerate and use within the stability window suggested for the shortest-lived component — typically four weeks or less.
- Reported side effects. Component literature describes injection-site irritation as the most common observation; the GHK-Cu copper content can cause local discoloration if administered superficially. Serious adverse events have not been documented for the combination because no controlled human safety data exists.
Sources
- 1.Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- 2.Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences.
- 3.Goldstein AL et al. (2012). Thymosin β4: a multifunctional regenerative peptide. Expert Opinion on Biological Therapy.
- 4.FDA 503A Bulk Drug Substances list — Category 2 (November 2023, BPC-157).